{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:11:57Z","timestamp":1788459117876,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008884","name":"Edward P. Evans Foundation","doi-asserted-by":"publisher","award":["R01 CA200707"],"award-info":[{"award-number":["R01 CA200707"]}],"id":[{"id":"10.13039\/100008884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013678","name":"Cancer Center, University of Colorado","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013678","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.eclinm.2025.103546","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:42:48Z","timestamp":1760143368000},"page":"103546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I\/II clinical trial"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6519-4860","authenticated-orcid":false,"given":"Daniel A.","family":"Pollyea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett M.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Amaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Gutman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Dell-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"Sohalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Haag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Schowinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenggang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7082-7204","authenticated-orcid":false,"given":"Sweta B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Ransom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Gillen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig T.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Pietras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.eclinm.2025.103546_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103546_bib2","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jama.2022.14578","article-title":"Diagnosis and treatment of myelodysplastic syndromes: a review","volume":"328","author":"Sekeres","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103546_bib3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103546_bib4","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103546_bib5","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103546_bib6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103546_bib7","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103546_bib8","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1038\/s41467-018-05984-x","article-title":"Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes","volume":"9","author":"Stevens","year":"2018","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103546_bib9","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the eastern cooperative oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103546_bib10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.eclinm.2025.103546_bib11","first-page":"2047","article-title":"Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes","volume":"141","author":"Zeidan","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103546_bib12","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/leu.2015.283","article-title":"Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides","volume":"30","author":"Zeidan","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103546_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103546_bib14","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103546_bib15","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103546_bib16","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world Health Organization classification of haematolymphoid tumours: myeloid and Histiocytic\/Dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103546_bib17","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1038\/s41375-021-01265-7","article-title":"Current challenges and unmet medical needs in myelodysplastic syndromes","volume":"35","author":"Platzbecker","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.eclinm.2025.103546_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fragi.2021.719010","article-title":"Stem cells in the myelodysplastic syndromes","volume":"2","author":"Zhan","year":"2021","journal-title":"Front Aging"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103546_bib19","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/joim.13535","article-title":"Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia","volume":"292","author":"Woll","year":"2022","journal-title":"J Intern Med"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103546_bib20","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1182\/blood.2023023533","article-title":"A road map of relapse in MDS after allo-HSCT","volume":"143","author":"Rodriguez-Sevilla","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2025.103546_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101072","article-title":"Current landscape of translational and clinical research in myelodysplastic syndromes\/neoplasms (MDS): proceedings from the 1(st) International Workshop on MDS (iwMDS) of the International Consortium for MDS (icMDS)","volume":"60","author":"Bewersdorf","year":"2023","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103546_bib22","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.clml.2023.12.008","article-title":"Real-world effectiveness of azacitidine in treatment-naive patients with higher-risk myelodysplastic syndromes","volume":"24","author":"Rajakumaraswamy","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103546_bib23","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/2040620712464882","article-title":"Azacitidine in the management of patients with myelodysplastic syndromes","volume":"3","author":"Khan","year":"2012","journal-title":"Ther Adv Hematol"},{"issue":"24","key":"10.1016\/j.eclinm.2025.103546_bib24","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2015.66.2510","article-title":"Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: north American intergroup study SWOG S1117","volume":"35","author":"Sekeres","year":"2017","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.eclinm.2025.103546_bib25","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","article-title":"Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML","volume":"6","author":"Ades","year":"2022","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.eclinm.2025.103546_bib26","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-Mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103546_bib27","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","article-title":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"11","author":"Zeidan","year":"2024","journal-title":"Lancet Haematol"},{"issue":"15","key":"10.1016\/j.eclinm.2025.103546_bib28","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study","volume":"41","author":"Sallman","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103546_bib29","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.2024025464","article-title":"Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes","volume":"145","author":"Garcia","year":"2025","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103546_bib30","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood.2019898114","article-title":"Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II","volume":"134","author":"Jones","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103546_bib31","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of amino acid metabolism selectively targets human leukemia stem cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025004791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025004791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T05:27:55Z","timestamp":1769059675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025004791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":31,"alternative-id":["S2589537025004791"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103546","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I\/II clinical trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103546","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103546"}}